NLS Pharmaceutics AG (NLSP) — Financial Flexibility Index

Latest as of September 2025: -1.43x

NLS Pharmaceutics AG (NLSP) has a Financial Flexibility Index of -1.43x as of September 2025. Free cash flow of $-2.07 Million (operating CF $-2.07 Million minus capex $0.00) represents -1% of total liabilities ($1.46 Million). Check how strategically is NLS Pharmaceutics AG's equity deployed to assess the company's strategic physical and investment asset allocation.

Financial Flexibility Index

-1.43x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-2.07 Million
Operating CF − Capex

Total Liabilities

$1.46 Million
USD

Capital Expenditures

$0.00
USD

NLS Pharmaceutics AG Financial Flexibility Index (2017–2024)

Historical Financial Flexibility Index trend for NLS Pharmaceutics AG across 8 annual periods. See NLS Pharmaceutics AG short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Annual Financial Flexibility Index for NLS Pharmaceutics AG (2017–2024)

Year-by-year free cash flow to debt coverage for NLS Pharmaceutics AG. For the full company profile including market capitalisation, see NLSP stock market capitalisation.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2024 -5.16x $-4.26 Million $-4.27 Million $826.76K ▼ -468.8%
2023 -0.91x $-9.68 Million $-9.68 Million $10.68 Million ▲ +60.8%
2022 -2.31x $-13.88 Million $-13.88 Million $6.00 Million ▲ +18.8%
2021 -2.85x $-14.90 Million $-14.94 Million $5.22 Million ▼ -3887.3%
2020 -0.07x $-729.38K $-729.39K $10.20 Million ▼ -226.5%
2019 -0.02x $-150.45K $-190.01K $6.87 Million ▲ +92.7%
2018 -0.30x $-2.69 Million $-2.73 Million $8.96 Million ▲ +44.6%
2017 -0.54x $-5.43 Million $-5.43 Million $10.01 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities